AbbVie plans to invest further in obesity.ABBV's Slowing Aesthetics Sales & Humira ErosionSales of AbbVie's blockbuster drug Humira are declining due to biosimilar erosion. Humira volume is rapidly eroding compared to other novel mechanisms (including Skyrizi and Rinvoq). Humira sales declined by almost 50% in the first quarter of 2025, primarily due to faster erosion of its share as a result of biosimilar competition, as well as further molecule compression in the United States.AbbVie is witnessing declining sales of Juvederm fillers in the United States and China due to challenging market conditions.